Posted by Michael Wonder on 16 Feb 2022
European Medicines Agency approves Pfizer’s 20 valent pneumococcal conjugate vaccine against invasive pneumococcal disease and pneumonia in adults
15 February 2022 - Apexxnar [pneumococcal polysaccharide conjugate vaccine (20 valent, adsorbed)] is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia.
Pfizer today announced that the EMA has approved the company’s 20 valent pneumococcal conjugate vaccine, which will be marketed in the European Union under the brand name Apexxnar.
